Orchid expects Enmetazobactam deal this quarter, eyes US sterile market
Out-licensing talks for the antibiotic are at an advanced stage in multiple regions. Management also outlined a new $1.2 billion US market initiative.
— 5 earlier stories on Orchid Pharma Ltd. →What's new
- Orchid expects to sign an out-licensing deal for Enmetazobactam this quarter.
- The company is building fill-finish capabilities to enter the US sterile cephalosporin market.
- The 7ACA fermentation project remains on track for commissioning in Q1 CY27.
Why this matters
The sterile cephalosporin push is a new capital commitment into a large, defined market. For a company of Orchid's size, it's a significant bet on execution. The Enmetazobactam deal, now expected this quarter, is the more immediate catalyst after repeated timeline slippages.
What we're watching
- Whether the Enmetazobactam out-licensing deal closes this quarter.
- Capital costs and timeline for the sterile fill-finish facility.
- Progress on the Dhanuka Laboratories merger, pending a court order.
The full read
Orchid Pharma is adding a second act. Alongside the long-running Enmetazobactam story, management said it is building sterile fill-finish capabilities to enter the US cephalosporin market. The target: 5-6 products in a $1.2 billion opportunity. This is new capital commitment. The first Enmetazobactam out-licensing deal, covering the US, Japan, and Latin America, is now due this quarter. Management repeated the $1-2 billion lifetime sales guidance but the timeline has been the sticking point. A signed deal would validate the asset. Separately, the 7ACA fermentation plant is on track for commissioning in Q1 CY27 and the Dhanuka Laboratories merger awaits a court order. The Enmetazobactam deal is the near-term test.
Questions answered
- What is the new US market opportunity Orchid Pharma is targeting?
- The company is building fill-finish capabilities to enter the US sterile cephalosporin market. Management said it is looking at 5-6 products that represent a combined $1.2 billion opportunity.
- What is the status of the Enmetazobactam out-licensing discussions?
- Talks are at an advanced stage in the US, Japan, and Latin America. Management said it expects to sign a deal this quarter and reiterated a $1-2 billion lifetime sales forecast for the antibiotic.
- Is there any update on the 7ACA fermentation project?
- The project remains on track. Management said it expects to commission the facility in the first quarter of calendar 2027.
- How does the Dhanuka Laboratories merger stand?
- The merger is pending. It is awaiting a formal court order before it can be completed.
Story so far
All notes on ORCHPHARMA →- 1 Jun 2026 · 6:44 PM IST Orchid expects Enmetazobactam deal this quarter, eyes US sterile market
- today NCLT clears Orchid-Dhanuka merger. Integration starts now.
- 10d ago Orchid Pharma lifts Enmetazobactam lifetime sales target to $2 billion
- 11d ago Orchid Pharma annual profit drops to ₹45.2 crore
- 11d ago Orchid Pharma profit falls 57% on higher costs; auditor flags US units